Previous 10 | Next 10 |
Gainers: OraSure Technologies (NASDAQ:OSUR) +5%, Iovance Biotherapeutics (NASDAQ:IOVA) +4%, Marqeta (NASDAQ:MQ) +3%, Chimerix (NASDAQ:CMRX) +3%, Ribbon Communications (NASDAQ:RBBN) +3%. Losers: Incannex Healthcare (NASDAQ:IXHL) -10%, CarParts.com (NASDAQ:PRTS) -5%, Eargo (NASDAQ:EAR) -5%...
The U.S. FDA has allowed an Investigational New Drug application from Iovance Biotherapeutics (NASDAQ:IOVA) to proceed for IOV-4001 for the treatment of unresectable or metastatic melanoma, and stage III or IV non-small cell lung cancer. IOV-4001 is the company's first tumor infiltrating...
Clinical Study Expected to Begin in 2022 to Investigate the Safety and Efficacy of IOV-4001 to Deliver TIL and PD-1 Inhibition within a Single Cancer Therapy First Genetically Modified Iovance TIL Therapy Leverages TALEN® technology Licensed from Cellectis to Inactiva...
SAN CARLOS, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced the acceptance of two abstracts for presentation at the upcoming American Associati...
Iovance Biotherapeutics, Inc. (IOVA) Q4 2021 Earnings Conference Call February 24, 2022 4:30 PM ET Company Participants Sara Pellegrino – Vice President, Investor and Public Relations Fred Vogt – Interim President and Chief Executive Officer Igor Bilinsky – Chief Operatin...
Iovance Biotherapeutics press release (NASDAQ:IOVA): Q4 GAAP EPS of -$0.63 misses by $0.07. Company had $602.1M in cash, cash equivalents, investments and restricted cash at December 31, 2021 compared to $635M at December 31, 2020. Shares +2.4%. For further details see: I...
SAN CARLOS, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today reported fourth quart...
SAN CARLOS, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its fourth quarter and full year financial results on Thursday, February 24, 2022. Managem...
AlloVir manufactures T cells ex vivo, off-the-shelf, for curing viral infections in HSCT patients. Its technology has similarities and differences with a number of other companies, discussed here. ALVR presents an interesting approach to an unmet medical need. For further de...
SAN CARLOS, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that Raj K. Puri, M.D., Ph.D., will join the Company as Executive Vice President, Regu...
News, Short Squeeze, Breakout and More Instantly...
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
2024-07-26 10:45:04 ET Pacific Biosciences of California Inc (PACB) PACB is trading UP for the last 5 days, and it at trading at $2.10 with volume of 3,952,245 and a one day change of $0.19 (9.97%). Pacific Biosciences of California Inc has a 52-week low of 1.16 and a 52-week high o...
2024-07-14 05:45:00 ET Biotech stocks like Iovance Biotherapeutics (NASDAQ: IOVA) often look appealing because they could experience enormous growth in relatively short periods of time. Plus, over the long term, successful biotech companies have the opportunity to blossom into large...